Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 3/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | ESRRA | P11474 | 7/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.31 |
| ▸ | ESRRB | O95718 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESRRG | P62508 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4598855 | 1.00 | SNCA (0.33) | SNCAARNR3C2NR3C1PGR | |
| SCHEMBL4815232 | 0.83 | CREBBP (0.37) | — | |
| SCHEMBL4629098 | 0.80 | AR (0.34) | ARNR3C2NR3C1PGRACHE | |
| SCHEMBL4570013 | 0.80 | AR (0.34) | ARNR3C2NR3C1PGRACHE | |
| SCHEMBL4813632 | 0.80 | CREBBP (0.35) | PGR | |
| SCHEMBL4565983 | 0.78 | — | — | |
| SCHEMBL4814159 | 0.77 | HDAC4 (0.33) | — | |
| SCHEMBL4445324 | 0.77 | HDAC4 (0.33) | — | |
| SCHEMBL4866034 | 0.77 | NR3C1 (0.35) | ARNR3C2NR3C1PGRESRRA | |
| SCHEMBL4816048 | 0.77 | KMT2A (0.34) | SNCAARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125825-A1 | ABCA1 ELEVATING COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080293757-A1 | ABCA1 ELEVATING COMPOUNDS | ABELMAN MATTHEW | 2008-11-27 | — | — | US | disclosed |
| US-7432276-B2 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7423045-B2 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| WO-2008079139-A1 | ABCA1 ELEVATING COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20070191379-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070010544-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191379-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | SNCA 4223/4885AR 3609/4885NR3C2 1416/4885 |
| US-20080293757-A1 | ABCA1 ELEVATING COMPOUNDS | ABCD3, ABCB4, CETP | SNCA 4223/4885AR 3609/4885NR3C2 1416/4885 |
| US-20070010544-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | SNCA 4223/4885AR 3609/4885NR3C2 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.